PRRT2 and Burkitt lymphoma: Further, we also found that the PKC signaling pathway is significantly activated in rituximab-resistant Burkitt’s lymphoma (BL) cells, and the application of the PKC inhibitor midostaurin could significantly enhance the pro-apoptotic effect of rituximab, leading to a significant therapeutic effect in tumor-bearing mouse models (27).